1. Home
  2. MGNX vs SGC Comparison

MGNX vs SGC Comparison

Compare MGNX & SGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

N/A

Current Price

$2.41

Market Cap

262.4M

Sector

Health Care

ML Signal

N/A

Logo Superior Group of Companies Inc.

SGC

Superior Group of Companies Inc.

N/A

Current Price

$13.37

Market Cap

214.8M

ML Signal

N/A

Company Overview

Basic Information
Metric
MGNX
SGC
Founded
2000
1920
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Apparel
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
262.4M
214.8M
IPO Year
2013
1994

Fundamental Metrics

Financial Performance
Metric
MGNX
SGC
Price
$2.41
$13.37
Analyst Decision
Buy
Strong Buy
Analyst Count
7
2
Target Price
$8.00
★ $18.00
AVG Volume (30 Days)
★ 968.0K
22.1K
Earning Date
11-20-2026
11-09-2026
Dividend Yield
N/A
★ 4.21%
EPS Growth
★ N/A
N/A
EPS
N/A
★ 0.14
Revenue
$149,500,000.00
★ $566,184,000.00
Revenue This Year
N/A
$3.02
Revenue Next Year
N/A
$3.83
P/E Ratio
★ N/A
$100.57
Revenue Growth
N/A
★ 0.09
52 Week Low
$1.32
$8.30
52 Week High
$5.08
$14.59

Technical Indicators

Market Signals
Indicator
MGNX
SGC
Relative Strength Index (RSI) 35.18 55.19
Support Level $1.71 $11.52
Resistance Level $3.46 $13.66
Average True Range (ATR) 0.31 0.63
MACD -0.02 0.07
Stochastic Oscillator 27.59 63.54

Price Performance

Historical Comparison
MGNX
SGC

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

About SGC Superior Group of Companies Inc.

Superior Group Of Companies Inc designs apparel products. The company operates through three segments: i) The Branded Products segment, under the brands BAMKO and HPI, produces and sells customized merchandising solutions, promotional products, and branded uniform programs. ii) The Healthcare Apparel segment, under the brands Wink and Fashion Seal Healthcare, manufactures and sells healthcare apparel including scrubs, lab coats, protective apparel, and patient garments. iii) The Contact Centers segment, through The Office Gurus entities, provides outsourced, nearshore, and onshore business process outsourcing (BPO), contact center, and call-center support services to customers in North America. The majority of the company's revenue is derived from the Branded Products segment.

Share on Social Networks: